Applications of [131I]m-iodobenzylguanidine ([131I]MIBG).
The development of the aralkylguanidine [131I]m-iodobenzylguanidine ([131I]MIBG) in the University of Michigan Nuclear Medicine Division has led to diagnostic and therapeutic evaluations of all the neuroendocrine tumors. These tumors share the property of uptake, storage and release of [131I]MIBG uptake in chromaffin granules. This property has allowed the detection of pheochromocytomas, the detection of metastases in 46% of such patients, the treatment of malignant pheochromocytomas, the detection of neuroblastoma metastases, the treatment of neuroblastomas and the detection of a percent of apudomas. We have learned how to improve our results and this is discussed.
Beierwaltes
W H
WH
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109.
D019797:3-Iodobenzylguanidine; D000310:Adrenal Gland Neoplasms / Q000000981:diagnostic imaging* / Q000532:radiotherapy; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D007462:Iodobenzenes / Q000627:therapeutic use; D009447:Neuroblastoma / Q000000981:diagnostic imaging* / Q000532:radiotherapy; D010673:Pheochromocytoma / Q000000981:diagnostic imaging* / Q000532:radiotherapy; D011877:Radionuclide Imaging
D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine